🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Teva Pharmaceutical Industries Limited TEVA PHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · Israel
https://www.tevapharm.com
Company Profile ↓
$38.98
+112.43% 1Y
Mkt Cap$45.46B
P/E64.97
P/B5.86
52W High$39.25
52W Low$18.34
Book Value$6.65
EPS (TTM)$0.60

Company Overview

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Why Investors Should Care

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $17.26B (+4.3% YoY); net profit $1.41B.
  • Trailing 12 Months Year-on-year growth — revenue -0.8%.
  • 5-Year Trend Long-term compounding — revenue CAGR -1.3%, profit CAGR -1.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-1.29%
1 Year:-0.80%

Compounded Profit Growth

5 Years:-1.18%
1 Year:-

Stock Price Performance

1 Year:+112.43%
6 Months:+32.40%
3 Months:+23.82%
1 Month:+4.03%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 99% of range
$18.34 $39.25
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)62.21 · Neutral
Price Performance
1M+4.03%
3M+23.82%
6M+32.40%
1Y+112.43%
Valuation vs Sector

P/E of 64.97 is above the sector median of 24.83 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 65.0.
  • Revenue declined at -1.3% CAGR over 5 years.
  • Earnings shrank at -1.2% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
64.97
Industry PE
24.83
Forward P/E
12.59
PEG Ratio
0.71
Book Value
$6.65
Price to Book
5.86
P/S
2.63
EV/EBITDA
13.80
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-1.29%
Profit 5Y
-1.18%
Revenue (YoY)
-0.80%
Earnings (YoY)
-

Profitability & Returns

ROCE
14.48%
ROE
9.69%
ROA
5.13%
Profit Margin
4.08%
Op Margin
4.03%
Gross Margin
52.46%
EPS (Latest Qtr)
$-0.49
EPS (TTM)
$0.60

Balance Sheet & Liquidity

Debt/Equity
2.18
Quick Ratio
0.46
Current Ratio
0.88
Debt
$16.89B
Total Assets
$39.86B
Current Assets
$13.76B
Working Capital
$490.00M

Ownership

Promoter Holding
0.52%
Chg in Prom Hold
0.52%
FII / Inst Holding
22.99%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$45.46B
Total Revenue (TTM)
$17.32B
EBITDA
$4.27B
Free Cash Flow
$2.22B
Operating Cash Flow
$1.90B
Shares Outstanding
1.17B
Gross Margin
52.46%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 TEVA Teva Pharmaceutical Industries Limited PHARMA 38.98 64.97 $45.46B 0.00% 14.48% 9.69% -1.29% -1.18%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue ----5.65B5.72B5.62B5.40B4.92B4.55B4.38B4.42B4.15B4.18B4.09B4.47B4.36B3.87B3.98B4.45B3.98B3.91B3.89B3.66B3.79B3.60B-3.66B3.88B3.85B3.82B4.16B4.33B--4.18B4.48B4.71B3.98B4.14B
Cost of Revenue -----------------------------------2.07B2.18B2.06B2.01B1.99B
Gross Profit 2.79B2.88B2.80B3.39B2.77B2.80B2.60B2.44B2.31B2.03B1.98B1.97B1.86B1.89B1.83B1.96B2.06B1.76B1.85B2.05B1.88B1.87B1.79B1.74B1.79B1.67B-1.58B1.80B1.85B1.77B2.02B2.15B--2.10B2.30B2.66B1.97B2.15B
Operating Expenses -----------------------------------1.20B1.23B1.39B1.21B2.00B
Operating Income ----895.00M-5.74B378.00M-1.52B-14.00M16.00M-134.00M-644.00M-81.00M-191.00M173.00M-4.34B-434.00M582.00M623.00M-713.00M-967.00M424.00M-940.00M-13.00M-654.00M344.00M-218.00M-5.00M-51.00M--899.00M1.07B1.27B759.00M149.00M
EBITDA -----------------------------------657.00M1.10B632.00M877.00M-19.00M
Interest Expense -----------------------------------203.00M209.00M292.00M201.00M195.00M
Pretax Income -----------------------------------203.00M646.00M80.00M437.00M-455.00M
Tax Provision ------------------------------------78.00M214.00M-390.00M67.00M121.00M
Net Income ----645.00M-5.97B595.00M-11.54B1.12B-176.00M-208.00M-2.89B-105.00M-689.00M-314.00M110.00M69.00M140.00M-4.35B150.00M77.00M207.00M292.00M-955.00M-251.00M61.00M-1.30B-220.00M-872.00M69.00M-139.00M-846.00M-437.00M--282.00M433.00M480.00M369.00M-576.00M
Diluted EPS 0.620.200.35-1.020.57-5.940.52-11.411.03-0.24-0.27-2.85-0.10-0.63-0.290.100.060.13-3.970.140.070.190.26-0.86-0.230.05-1.17-0.20-0.780.06-0.12-0.75-0.39--0.240.370.410.31-0.49
R&D Expense --------54.00M--------------54.00M----------------

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 19.65B21.90B21.85B18.27B16.89B16.66B15.88B14.93B15.85B16.54B17.26B
Cost of Revenue -------7.95B8.20B8.48B8.32B
Gross Profit 11.36B11.65B10.62B8.30B7.54B7.73B7.59B6.97B7.64B8.06B8.94B
Operating Expenses -------4.28B4.45B4.70B4.99B
Operating Income 3.35B2.15B-17.48B-1.64B-443.00M-3.57B1.72B2.69B3.19B3.36B3.95B
EBITDA --------925.00M1.56B777.00M3.14B
Interest Expense -------930.00M1.03B1.00B916.00M
Pretax Income --------3.16B-624.00M-1.28B1.22B
Tax Provision --------643.00M-7.00M676.00M-180.00M
Net Income 1.59B329.00M-16.27B-2.15B-999.00M-3.99B417.00M-2.45B-559.00M-1.64B1.41B
Diluted EPS 1.820.07-16.26-2.35-0.91-3.640.38-2.12-0.50-1.451.21
R&D Expense 35.00M422.00M175.00M114.00M---98.00M---

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2014Dec 2015Jan 2016Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Dec 2024Dec 2025
Total Assets ---93.06B70.61B60.68B57.47B50.64B-45.93B44.25B44.01B43.46B43.10B42.09B43.48B39.33B40.75B
Current Assets -----------12.05B---12.48B12.55B13.95B
Cash & Equivalents 2.23B6.95B-988.00M963.00M1.78B1.98B2.18B---2.80B---3.23B3.30B3.56B
Inventory -----------3.83B---4.02B3.01B3.18B
Receivables -----------3.70B---3.41B3.06B3.71B
Total Liabilities ---58.06B51.87B44.89B42.41B39.58B-36.12B34.75B35.41B34.96B35.51B34.71B35.35B33.61B32.83B
Current Liabilities ---18.49B17.92B14.32B13.67B13.16B---11.47B---12.25B12.80B13.46B
Long Term Debt ---32.52B28.83B------19.10B---18.16B16.00B14.99B
Total Debt -----------21.56B---20.15B18.08B17.09B
Total Equity 23.36B29.93B29.93B33.34B17.36B14.71B13.97B10.03B-9.81B9.51B7.80B8.50B7.59B7.39B7.51B5.37B7.91B
Shares Outstanding -----------1.22B---1.23B1.24B1.26B

Cash Flows (Annual)

Figures in USD.

Metric Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 5.54B3.89B2.23B2.45B748.00M1.22B-1.59B1.37B1.25B1.65B
Investing Cash Flow -5.57B-34.41B3.45B1.87B1.35B863.00M-656.00M968.00M792.00M737.00M
Financing Cash Flow 4.80B25.22B-5.75B-3.35B-1.93B-1.89B--1.49B-1.91B-1.79B-2.15B
Capital Expenditure -772.00M-901.00M-874.00M-651.00M-525.00M-578.00M--548.00M-526.00M-498.00M-501.00M
Free Cash Flow 4.77B2.99B1.35B1.79B223.00M638.00M-1.04B842.00M749.00M1.15B
Net Change in Cash -------759.00M423.00M247.00M235.00M
Share Buybacks 439.00M00--------

Ratios (Annual)

Figures in %.

Metric Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 57.8%53.2%48.6%45.4%44.6%46.4%47.8%46.7%48.2%48.7%51.8%
Operating Margin % 17.1%9.8%-80.0%-9.0%-2.6%-21.4%10.8%18.0%20.2%20.3%22.9%
Net Margin % 8.1%1.5%-74.4%-11.8%-5.9%-24.0%2.6%-16.4%-3.5%-9.9%8.2%
ROE % 5.3%1.0%-93.7%-14.6%-7.2%-39.8%--31.3%-7.4%-30.5%17.8%
ROCE % -2.9%-33.2%-3.5%-1.0%-9.5%-8.3%10.2%12.7%14.5%

Shareholding Pattern

Insiders
0.52%
Institutions
22.99%
Public Float
23.11%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 5.48% 63.89M $2.49B
2 Harel Insurance Investments & Financial Services Ltd. 4.13% 48.14M $1.88B
3 Phoenix Financial Ltd. 3.68% 42.93M $1.67B
4 WCM Investment Management, LLC 3.55% 41.32M $1.61B
5 Clal Insurance Enterprises Holdings Ltd 3.48% 40.60M $1.58B
6 Menora Mivtachim Holdings Ltd. 3.42% 39.85M $1.55B
7 Migdal Insurance & Financial Holdings Ltd. 3.34% 38.92M $1.52B
8 NORGES BANK 2.77% 32.30M $1.26B
9 FMR, LLC 2.60% 30.26M $1.18B
10 Lingotto Investment Management LLP 1.73% 20.21M $787.63M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TEVA

No recent headlines available.

TEVA — Frequently Asked Questions

What is the current share price of Teva Pharmaceutical Industries Limited (TEVA)?

As of 2026-09-19 21:16 PDT, Teva Pharmaceutical Industries Limited (TEVA) trades at $38.98 on NYSE. Its 52-week range is $18.34 to $39.25.

What is the market capitalisation of TEVA?

Teva Pharmaceutical Industries Limited (TEVA) has a market capitalisation of $45.46B on NYSE.

What is the P/E ratio of TEVA?

TEVA trades at a trailing price-to-earnings (P/E) ratio of 64.97. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 5.86.

What is the return on equity (ROE) of TEVA?

TEVA has a return on equity (ROE) of 9.69%. Its return on capital employed (ROCE) is 14.48%.

Is TEVA a good stock to buy?

This page provides a data-driven analysis of Teva Pharmaceutical Industries Limited (TEVA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space